Sort
51,593 grants matching “hepatitis”
Nutrient overload, insulin resistance, and hepatic mitochondrial dysfunction
$697,269Elizabeth Jane Parks · University Of Missouri-Columbia · R01 · FY2017 · DK
Defining mechanisms of disease and repair in a viral model of multiple sclerosis
$697,256Thomas E Lane · University Of California-Irvine · R35 · FY2020 · NS
Them1-Mediated Metabolic Regulation and Pathogenic Role in NAFLD
$697,241David E Cohen · Brigham And Women'S Hospital · R01 · FY2023 · DK
Hepatic Gene Transfer for Treatment of Hemophilias A & B
$697,224Mark A Kay · Stanford University · R01 · FY2022 · HL
Hepatic Gene Transfer for Treatment of Hemophilias A & B
$697,224Mark A Kay · Stanford University · R01 · FY2019 · HL
Hepatic Gene Transfer for Treatment of Hemophilias A & B
$697,224Mark A Kay · Stanford University · R01 · FY2020 · HL
Hepatic Gene Transfer for Treatment of Hemophilias A & B
$697,224Mark A Kay · Stanford University · R01 · FY2021 · HL
Immune function and the risk of cvd among HIV infected and uninfected veterans
$697,207Matthew S Freiberg · Vanderbilt University Medical Center · R01 · FY2016 · HL
Therapeutic and mechanistic significance of altered metabolism of HIV medicines by alcohol- or alcohol/synthetic opioid combination
$697,172Bingfang Yan · University Of Cincinnati · R01 · FY2024 · AA
Therapeutic and mechanistic significance of altered metabolism of HIV medicines by alcohol- or alcohol/synthetic opioid combination
$697,172Bingfang Yan · University Of Cincinnati · R01 · FY2025 · AA
Therapeutic and mechanistic significance of altered metabolism of HIV medicines by alcohol- or alcohol/synthetic opioid combination
$697,172Bingfang Yan · University Of Cincinnati · R01 · FY2023 · AA
Statin Intervention to Slow the Time to Hepatocellular Carcinoma Recurrence in Cirrhotics Awaiting Liver Transplantation
$697,142Shehnaz Khursheed Hussain · Cedars-Sinai Medical Center · R01 · FY2017 · CA
Defining targets of protective immunity to vivax malaria using human monoclonal antibodies
$697,088Christopher L King · Case Western Reserve University · R01 · FY2024 · AI
Development of CB1 Monoclonal Antibodies for Treating NASH
$697,083Benjamin Jacob Doranz · Integral Molecular · R44 · FY2019 · DK
An HB Vaccine Model For HIV Vaccine Trials in Drug Users
$697,045University Of Texas Hlth Sci Ctr Houston · R01 · FY2004 · DA
HEPATITIS C CLINICAL TRIAL-CLINICAL CENTERS
$697,017University Of Southern California · N01 · FY2000 · DK
Applying a Human Liver Microphysiology System to Develop Therapeutic Strategies for Non-Alcoholic Fatty Liver Disease (NAFLD)
$696,977D. Lansing Taylor · University Of Pittsburgh At Pittsburgh · R01 · FY2018 · DK
Role of Factor XII in Thrombo-Inflammatory Complications of Sickle Cell Disease
$696,975Rafal L Pawlinski · Univ Of North Carolina Chapel Hill · R01 · FY2025 · HL
Molecular Prognostic Indicators in Liver Cirrhosis and Cancer
$696,850Yujin Hoshida · Icahn School Of Medicine At Mount Sinai · R01 · FY2014 · DK
Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell LungCancer
$696,801Renier Joseph Brentjens · Roswell Park Cancer Institute Corp · U01 · FY2025 · CA
The Progression of Hepatitis C Among IDUs
$696,769Johns Hopkins University · R01 · FY2003 · DA
In Vivo And In Vitro Studies Of Hepatitis E Virus
$696,744Suzanne Emerson · Niaid Extramural Activities · Z01 · FY2007 · AI
Antiretroviral Therapy and the Hepatitis C Virus
$696,735Kenneth E Sherman · University Of Cincinnati · R01 · FY2007 · AI
Risk Factors for AIDS Among Intravenous Drug Users
$696,700Don C Des Jarlais · Beth Israel Medical Ctr (New York) · R01 · FY2008 · DA
Paneth cells-derived IL-17A and liver ischemia reperfusion injury
$696,652H. Thomas Lee · Columbia University Health Sciences · R01 · FY2025 · DK